Crispr Theraptc (NASDAQ: CRSP) and Charles River Laboratories International (NYSE:CRL) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Crispr Theraptc and Charles River Laboratories International, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Crispr Theraptc 0 4 4 0 2.50
Charles River Laboratories International 0 5 4 0 2.44

Crispr Theraptc presently has a consensus price target of $23.08, indicating a potential upside of 21.05%. Charles River Laboratories International has a consensus price target of $103.17, indicating a potential downside of 10.42%. Given Crispr Theraptc’s stronger consensus rating and higher probable upside, equities analysts clearly believe Crispr Theraptc is more favorable than Charles River Laboratories International.

Valuation & Earnings

This table compares Crispr Theraptc and Charles River Laboratories International’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Crispr Theraptc $10.18 million 76.04 -$79.90 million ($3.47) -5.50
Charles River Laboratories International $1.81 billion 3.03 $435.89 million $3.81 30.23

Charles River Laboratories International has higher revenue and earnings than Crispr Theraptc. Crispr Theraptc is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

23.9% of Crispr Theraptc shares are held by institutional investors. Comparatively, 95.1% of Charles River Laboratories International shares are held by institutional investors. 40.0% of Crispr Theraptc shares are held by insiders. Comparatively, 2.2% of Charles River Laboratories International shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Crispr Theraptc and Charles River Laboratories International’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Crispr Theraptc -406.61% -47.46% -22.13%
Charles River Laboratories International 10.13% 27.02% 8.84%

Summary

Charles River Laboratories International beats Crispr Theraptc on 7 of the 11 factors compared between the two stocks.

Crispr Theraptc Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company’s clients’ manufacturing activities.

Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.